Learn the Latest In CAR T with ASTCT Webinars

Article

Join ASTCT for a series of webinars that focus on topics relating to CAR T.

ASTCT has hosted a series of webinars focused on a variety of topics related to CAR T therapies. Topics include CAR T vs. transplant, CAR T toxicity management, how CAR T therapy works and much more. This series is designed to give medical professionals the information, research and tools you need to better understand and integrate CAR T therapies into your practice.

Access the webinar series here.

Recent Videos
Sympathomimetic effects related to psilocybin may preclude use among patients with coronary artery disease or those with a high risk of stroke.
Psilocybin-assisted psychotherapy may be integrated into pre-existing behavioral health aspects of comprehensive cancer treatment.
Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.
Survivors of cancer may experience an increased risk of having organ, cardiac, or lung disease following prior anti-cancer therapy.
Performing ablation and injecting tumor sites with immunotherapy may be “synergistic”, according to Jason R. Williams, MD, DABR.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Related Content
FDA Clears Investigational New Drug Application for R-5780 in Solid Tumors

FDA Clears Investigational New Drug Application for R-5780 in Solid Tumors

Tim Cortese
January 15th 2025
Article

The RISE R-5780-01 trial will evaluate the safety and tolerability of R-5780 in patients with melanoma, basal cell carcinoma, or squamous cell carcinoma.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Nearly half of patients with an ICD had a device programming encounter near the end of life, which could present an opportunity to discuss goals of care.

Aggressive End-of-Life Care More Likely in ICD Users with Advanced Cancers

Roman Fabbricatore
January 14th 2025
Article

Nearly half of patients with an ICD had a device programming encounter near the end of life, which could present an opportunity to discuss goals of care.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Jessica Cheng, MD
September 9th 2024
Podcast

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

According to the FDA, biopsies should be optional in clinical protocol when information will be used to evaluate only non-key secondary end points.

FDA Issues Guidance Considerations for Tissue Biopsies in Clinical Trials

Roman Fabbricatore
January 7th 2025
Article

According to the FDA, biopsies should be optional in clinical protocol when information will be used to evaluate only non-key secondary end points.

A study observed differences between expected and observed cancer incidence in 2020 and 2021 to evaluate the pandemic’s disruption of cancer detection.

Pandemic Cancer Incidence Observance Shows Further Recovery Still Needed

Roman Fabbricatore
January 6th 2025
Article

A study observed differences between expected and observed cancer incidence in 2020 and 2021 to evaluate the pandemic’s disruption of cancer detection.